pharma · Hepatocellular Carcinoma · Obesity
Hospital Authority
Hospital Authority, Hong Kong
Hospital Authority, Hong is a pharma organization headquartered in CN. Primary therapeutic focus areas include Hepatocellular Carcinoma, Obesity, Acute Kidney Injury, Nasopharyngeal Carcinoma, Coronary Artery Disease. No
Company details
- Status
- Public
- HQ
- Hospital Authority Building, 147B Argyle Street, Kowloon, Hong Kong, 852, HK, CN
- Founded
- 1991
- Employees
- 12,669
- Programs
- 322
- Drugs
- 301
- Patents
- 0
Intravenous methylene blue administration
Phase 3 · small molecule · Severe Sepsis
Intravenous methylene blue administration for Severe Sepsis is a Phase 3 program (small_molecule) at Hospital Authority, Hong Kong with 1 ClinicalTrials.gov record(s).
Internal code B-1210/173-002
Full intelligence profile for this program is being prepared.
At a glance
- Sponsor
- Hospital Authority, Hong Kong
- Phase
- Phase 3
- Modality
- small_molecule
- Indication
- Severe Sepsis
- Status
- active
- Trials
- 1